Peptide Sciences Is Dead: Inside the Rise and Fall of the Gray Market's Biggest Name
The largest research peptide vendor in America just walked away. Here's how they built a nine-figure empire in a legal gray zone, why they shut it down, and what it means for everyone who depended on
THE PEPTIDE LIST • Mar 06, 2026
At approximately 2:00 PM Eastern on March 6, 2026, visitors to peptidesciences.com were greeted by three sentences inside a red-bordered box on an otherwise blank white page. No product catalog. No research library. No shopping cart. Just a goodbye: “After careful consideration, Peptide Sciences has made the decision to voluntarily shut down operations and discontinue the sale of our research products.”
Thirteen words to close what was, by most credible estimates, the single largest research peptide vendor in the United States. A company that moved over a million website sessions per month. That generated $7.4 million in online sales in December 2025 alone, according to e-commerce analytics firm Grips Intelligence. That accepted payment through Venmo, Zelle, Cash App, cryptocurrency, and credit cards because traditional payment processors kept cutting them off.
Peptide Sciences didn’t get raided. They didn’t get indicted. They didn’t lose a lawsuit. They read the room, counted their money, and closed the laptop.
Peptide Sciences: By the Numbers
Within hours of the announcement, the peptide internet erupted. Andrew Huberman, the Stanford neuroscientist with 7 million X followers, quote-tweeted the news: “Assuming this is real it may have something to do with their ‘must pay by Venmo to the following name’ (at least that’s how it used to be). FDA is easing up on some aspects of peptides but gray market is about to get CRUSHED.”
He wasn’t wrong. But the full story is more interesting than a hot take.
How Peptide Sciences Became the Amazon of Gray Market Peptides
Daniel Brzezinski, a biochemist, built Peptide Sciences into something the research peptide world had never seen: a vendor that looked and felt like a legitimate pharmaceutical company. The company’s registered address, 2831 St. Rose Parkway, Suite 362, Henderson, NV 89052, sounds impressive until you look it up. It’s a virtual mailbox at St. Rose Executive Suites, a coworking center that offers mail forwarding and live receptionist services. Not a laboratory. Not a warehouse. A mailbox.
The domain peptidesciences.com was registered on December 6, 2009, though the company’s own About page claimed a founding date of 1990. That 19-year discrepancy has never been explained. What’s clear is that by the early 2010s, the site was operational and growing, and by the time it shut down, it was being run by an estimated three to five employees generating revenue that dwarfed most licensed pharmaceutical operations.
The website was clean, professional, and loaded with scientific content. Product pages included molecular weights, amino acid sequences, and references to published research. Certificates of Analysis were provided for every batch. The branding was clinical: white backgrounds, sans-serif fonts, the kind of design language you’d expect from a biotech supplier, not a gray market operation selling compounds that everyone knew were going into human bodies.
This was the genius of the model. Every other research peptide vendor looked like what they were: anonymous storefronts with sketchy payment portals and disclaimers written by someone who’d never seen the inside of a law school. Peptide Sciences looked like science.
Pharmaceutical-grade presentation. Venmo-grade payment infrastructure.
They built a research library. Published peptide guides. Maintained a blog with references to peer-reviewed studies. The entire operation projected an air of institutional legitimacy that made customers feel like they were buying from a university supplier, not a company that literally had a page called /venmo-payment-instructions-3 on their website.
That URL tells you everything about the tension at the heart of the business. A company sophisticated enough to build a world-class e-commerce operation, but operating in a regulatory space so precarious that Visa and Mastercard wouldn’t reliably process their transactions. When your checkout page lists Venmo, Zelle, and Cash App alongside cryptocurrency, that’s not offering “flexible payment options.” That’s a company that keeps getting dropped by payment processors and has learned to build redundancy into the one part of the business that matters most: getting paid.
The Product Catalog
At its peak, Peptide Sciences offered over 100 research peptides spanning virtually every category the biohacking and longevity communities cared about:
Growth hormone secretagogues: CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, MK-677
Tissue repair and recovery: BPC-157, TB-500 (Thymosin Beta-4), GHK-Cu
Weight loss and metabolic: Semaglutide, tirzepatide, retatrutide, AOD-9604, MOTS-c
Cognitive and neuroprotective: Selank, Semax, Dihexa, PE-22-28
Immune modulation: Thymosin Alpha-1, LL-37
Sexual health: PT-141 (Bremelanotide), Melanotan II
Longevity: Epitalon, FOXO4-DRI, NAD+ peptides
Every product came with the industry-standard disclaimer: “For research use only. Not for human consumption.” Every customer clicked through an attestation confirming research intent. And virtually everyone who placed an order was injecting, inhaling, or swallowing these compounds themselves.
This transparent fiction sustained the entire research peptide industry for over a decade. And legally, it provided essentially zero protection.
Healthcare law firm Frier Levitt has analyzed FDA enforcement actions against “research only” peptide vendors. Their conclusion: the FDA considers a product’s classification based on its intended use, not its disclaimers. When websites include dosage guides, reconstitution instructions, or link to forums discussing human use, the “research only” label is legally meaningless. The FDA has explicitly called such disclaimers “a ruse to avoid FDA scrutiny.” The criminal conviction of Paradigm Peptides’ founders, who maintained research-only disclaimers while their blog published dosage and cycle articles, proved this in federal court.
Peptide Sciences just executed the fiction better than anyone else. Better branding. Better content. Better packaging. Same legal exposure.
The Scale Nobody Talked About
The numbers paint a picture that the peptide community rarely discussed openly. According to traffic analytics from Semrush, peptidesciences.com attracted 990,450 visits in November 2025 alone, with organic search traffic growing 8.33% month-over-month. Their global website ranking fluctuated between 32,000 and 41,000, putting them in the same traffic tier as mid-sized SaaS companies and regional news outlets.
E-commerce intelligence from Grips tells an even more striking story. In December 2025, the site generated $7.45 million in online sales with a 3.0-3.5% conversion rate across 1.15 million sessions. Even accounting for seasonal variation, those numbers suggest annual revenue well into nine figures over the company’s lifetime.
Here’s the detail that puts the scale in perspective: SimilarWeb’s demographic data shows the largest visitor age group was 55 to 64 years old. These aren’t graduate students ordering reagents for bench work. These are aging adults looking for anti-aging peptides, growth hormone secretagogues, and weight loss compounds. The “research use only” disclaimer was a legal fiction, and the traffic data proves it.
Three to five employees. A virtual mailbox. Revenue that likely exceeded most of the 72 FDA-registered 503B outsourcing facilities in the country. Peptide Sciences was running a pharmaceutical-scale operation under a research chemical disclaimer, and they did it for over a decade.
The Squeeze That Made Walking Away the Smart Play
Peptide Sciences didn’t wake up on March 6th and decide to close on a whim. The walls had been closing in for months, and the company appeared to be systematically winding down its highest-risk product lines before pulling the plug entirely.
The GLP-1 Cash Cow Dies
The biggest revenue driver in the research peptide market from 2023 through early 2026 wasn’t BPC-157 or TB-500. It was GLP-1 agonists: semaglutide, tirzepatide, and the next-generation triple agonist retatrutide. When brand-name Ozempic and Mounjaro cost $900 to $1,300 per month without insurance, research peptide vendors offered the same molecules for $150 to $300. The economics were irresistible, and the customer base exploded.
Then the FDA started swinging.
In September 2025, the agency issued more than 50 warning letters to companies compounding or manufacturing GLP-1 drugs. These weren’t just aimed at pharmacies. The letters targeted false or misleading statements on websites and promotional materials, specifically claims that products were “generic versions” or contained the “same active ingredient” as FDA-approved drugs.
The SAFE Drugs Act (Safeguarding Americans from Fraudulent and Experimental Drugs Act), introduced in early 2026, went further still, prohibiting the sale of research chemicals biologically identical to FDA-approved drugs without a New Drug Application. Almost overnight, vendors across the industry began scrubbing their catalogs. Semaglutide, tirzepatide, and retatrutide vanished from websites that had been selling them openly for years.
Peptide Sciences had already started pulling GLP-1s before the full shutdown. Their statement at the time: “We have discontinued several items, including Semaglutide, Tirzepatide, Retatrutide, and MK-677, as part of our routine compliance updates and alignment with evolving industry compliance guidance.” The word “routine” was doing a lot of heavy lifting in that sentence.
To understand the revenue impact, consider that Hims & Hers Health, a single telehealth company operating in the regulated market, earned $225 million from compounded semaglutideduring the shortage period. The gray market GLP-1 segment across all vendors was likely worth multiples of that. When you cut that revenue stream off overnight, the math on continuing operations changes dramatically.
For Peptide Sciences, this wasn’t a compliance adjustment. It was an amputation of their most profitable product lines.
The domino effect: each FDA enforcement action made the next one more likely.
The 2023 Warning Letter
Peptide Sciences didn’t escape FDA attention entirely. In 2023, the agency issued a warning letter to the company for making health claims about BPC-157 and TB-500 on their website. References to “healing” and “recovery” crossed the line from research chemical sales into drug marketing. The company restructured their website and marketing materials to comply.
This is significant because it establishes direct FDA contact with Peptide Sciences. The agency knew who they were. They were on the radar. Every subsequent enforcement escalation, from the 50+ GLP-1 warning letters to the Amino Asylum raid, would have landed differently when you already had a letter in your file.
The Quality Problem
Here’s a detail the peptide community doesn’t love discussing: independent testing repeatedly flagged quality concerns with Peptide Sciences’ products.
Finnrick Analytics, a third-party testing platform that has become the de facto quality watchdog for the research peptide market, gave Peptide Sciences’ retatrutide a rating of E (Bad) based on 34 independent laboratory samples. Their latest test, dated August 4, 2025, confirmed the poor rating.
The problems weren’t subtle. Finnrick found quantities diverging by up to 50% from advertised amounts. In at least one February 2025 test, a compound was incorrectly identified as retatrutide entirely. For context, Finnrick rates vendors on an A-through-E scale across 136 vendors and 1,941 independent tests. An E rating means consistent quality failures across multiple samples. For a company that built its entire brand on scientific credibility and institutional-grade quality, this was devastating.
One X user, Tom Howard, put it bluntly: “How did I know Peptide Sciences sold me fake Retatrutide? I was shown pre-release data from Finnrick.”
When your flagship product category (GLP-1s) is getting legislated out of existence, the FDA already has your name in their files, and your product quality is getting exposed by independent testing, the calculus changes fast.
The Enforcement Escalation
The 12 months before Peptide Sciences shut down saw the most aggressive regulatory enforcement campaign the research peptide market has ever experienced:
December 2024: FDA issues warning letters to Prime Peptides, Xcel Peptides, SwissChems, and Summit Research for selling semaglutide, tirzepatide, and retatrutide as unapproved drugs.
June 2025: FDA raids Amino Asylum’s warehouse. Website goes offline. Payment processing terminated. Pending orders frozen. As of March 2026, the site remains dark.
September 2025: FDA issues 50+ warning letters to GLP-1 compounders and manufacturers, with confirmed DOJ involvement. The Center for Drug Evaluation and Research (CDER) warning letters jumped 50% in fiscal year 2025.
December 2025: Pinnacle Professional Research (dba Pinnacle Peptides) receives an FDA warning letter for marketing SARMs.
Early 2026: New legislation prohibits selling research chemicals identical to FDA-approved drugs without an NDA. Vendors begin mass catalog purges.
March 6, 2026: Peptide Sciences posts three sentences and goes dark.
The scale of the problem the FDA was responding to is staggering. LegitScript, a compliance monitoring firm used by major payment processors, reported 308% more problematic peptide advertisements in 2024 compared to 2023, and 678% more compared to 2022. E-commerce peptide products grew 276% over five years. The gray market wasn’t shrinking. It was exploding. And that explosion is what made the crackdown inevitable.
The pattern is unmistakable. The FDA moved from warning letters to warehouse raids to legislative ammunition. Each escalation raised the stakes. Each enforcement action made the next one more likely. Peptide Sciences saw the trajectory and made a calculation that every sophisticated business operator would understand: the expected value of continuing operations had turned negative.
The Huberman Angle
Within hours of the shutdown announcement, Andrew Huberman weighed in with a quote-tweet that reached 224,000 views:
“Assuming this is real it may have something to do with their ‘must pay by Venmo to the following name’ (at least that’s how it used to be). FDA is easing up on some aspects of peptides but gray market is about to get CRUSHED.”
Huberman’s comment highlights a tension he’s been navigating publicly for years. He’s arguably done more to popularize peptide therapeutics than any other public figure, dedicating multiple podcast episodes to their benefits and mechanisms. He’s also been the most prominent voice warning people away from the gray market sources that actually supply them.
In December 2022, he tweeted: “Note: avoid gray market peptides, they are often contaminated with LPS. Work with a qualified MD.” In January 2025: “Many of the gray market peptide sources out there are contaminated with lipopolysaccharide. I would only recommend working with an MD and a quality compounding pharmacy.”
And in February 2026, he predicted: “Expect a massive surge in compounding pharmacies, explicit warning labels on gray market peptides... and steep penalties for any venue besides Lilly selling Retatrutide.”
His March 6th comment, responding to peptide influencer Rory (@rorynotsorry) who posted the shutdown notice, completes the arc. Huberman has been telling his audience for four years that this moment was coming. Now it’s here.
The broader point Huberman keeps making is worth sitting with: the FDA isn’t killing peptides. They’re killing the gray market distribution channel. The molecules aren’t going away. The unregulated vendors selling them without oversight, quality control, or accountability are.
The Smartest Exit in the Gray Market
Let’s be direct about what likely happened here, because the industry commentary is dancing around it.
Peptide Sciences built a business that, by all available e-commerce data, generated revenue in the hundreds of millions of dollars over its lifetime. They did this by selling research chemicals in a regulatory gray zone where enforcement was sporadic and penalties were manageable.
Then three things changed simultaneously:
The highest-margin products (GLP-1s) became legally untouchable. New legislation and 50+ warning letters made continued sales of semaglutide, tirzepatide, and retatrutide an invitation to federal prosecution rather than a calculated risk.
The enforcement apparatus escalated from letters to raids. Amino Asylum getting their warehouse raided by the FDA in June 2025 sent a message that the era of “we’ll send you a letter and you’ll ignore it” was over.
The quality facade cracked. Independent testing from Finnrick exposed product quality issues that undermined the brand’s core value proposition: that you were getting pharmaceutical-grade products from a scientifically rigorous supplier.
When you’ve already made your fortune, the remaining inventory isn’t worth the legal exposure, and the competitive moat (brand trust) is eroding, the rational move is obvious. Close the website. Walk away clean. Let someone else be the next Amino Asylum.
As we noted in our initial analysis on X: “Peptide Sciences made a quarter billion and walked away at the top. Why fight the FDA in court for a decade when you can just close the laptop and retire? Smartest exit in the gray market.”
This isn’t a tragedy. It’s a business decision.
What This Means for the Peptide Market
For Consumers
If you were a Peptide Sciences customer, your supply just evaporated. And the options for replacing it are getting worse, not better.
The vendors still operating in the research peptide space fall into two categories: established names that are likely next on the FDA’s list, and newer operations with unknown quality standards filling the vacuum. Neither option is reassuring.
The Category 2 ban already eliminated compounding pharmacy access to BPC-157, TB-500, CJC-1295, Ipamorelin, and 13 other popular peptides. GLP-1 research chemicals are legislated off the market. The gray market’s biggest and most trusted name just closed.
What remains? Legitimate compounding pharmacies can still compound sermorelin, thymosin alpha-1, PT-141, LL-37, and other peptides not on the Category 2 list. But you’ll need a prescription, a physician relationship, and you’ll pay more. That’s the trade-off between regulated and unregulated markets: oversight costs money, but you actually know what’s in the vial.
We maintain a verified provider directory of 823+ peptide providers, including licensed compounding pharmacies and telehealth clinics that operate within the current regulatory framework.
For the Industry
The gray market vendor graveyard: ten names and counting since late 2024.
The body count is stacking up. Since late 2024, at least ten major gray market peptide vendors have been shut down, raided, warned, or criminally prosecuted:
Peptide Sciences (voluntary shutdown, March 2026)
Amino Asylum (FDA warehouse raid, June 2025)
Paradigm Peptides (founders Matthew Kawa and Jennifer Stechkober entered guilty pleas, December 2025; products advertised as SARMs contained undisclosed testosterone)
Tailor Made Compounding (guilty plea, $1.79M forfeiture for distributing BPC-157, CJC-1295, Ipamorelin as unapproved drugs)
SwissChems (FDA warning letter, also named in Eli Lilly ITC complaint)
Prime Peptides (FDA warning letter)
Xcel Peptides (FDA warning letter)
Summit Research (FDA warning letter)
Pinnacle Peptides (FDA warning letter)
Science.bio (ceased operations, January 2026)
Note the escalation pattern: warning letters in late 2024, a warehouse raid in mid-2025, criminal guilty pleas by late 2025, and the biggest name walking away in early 2026. That’s not a coincidence. That’s a coordinated campaign. And Eli Lilly’s ITC complaint resulted in a General Exclusion Order banning ALL importation of products containing or purporting to contain tirzepatide. Big Pharma isn’t just watching the FDA work. They’re using trade law to shut down the supply chain at the border.
Peptide Sciences’ exit accelerates a consolidation that was already underway. The research peptide market is bifurcating into two distinct futures:
The regulated path: Licensed 503A and 503B compounding pharmacies, telehealth clinics with legitimate prescribing relationships, and eventually (possibly) a new 503C regulatory category that creates a middle ground for peptide compounding.
The underground path: Smaller, more anonymous vendors. International sourcing. Cryptocurrency-only payment. No quality testing. No brand reputation. No customer service. The gray market doesn’t disappear when you shut down its most visible participant. It just gets darker.
The vendors watching Peptide Sciences’ exit are doing their own math right now. Every month of continued operation is a month of accumulated legal risk. The question isn’t whether the FDA will come for them. It’s whether they’ll have already cashed out when it happens.
For Pharma
This is exactly the outcome pharmaceutical companies wanted. Every research peptide customer who loses their gray market source becomes a potential customer for FDA-approved products, or drops out of the market entirely.
It’s notable that Hims House, an account focused on Hims & Hers Health ($HIMS), was one of the first to tweet the Peptide Sciences shutdown, tagging $HIMS, $LLY (Eli Lilly), and $NVO (Novo Nordisk). The financial implications are clear: every dollar that was flowing to gray market peptide vendors is now either going to legitimate pharmaceutical channels or evaporating. Either way, the competition just got weaker.
The Bigger Picture: A Market in Transition
Peptide Sciences’ shutdown is a data point in a larger story that we’ve been tracking since launching ThePeptideList. The peptide market is undergoing a forced evolution from gray market self-experimentation to regulated therapeutic access.
This transition is messy, painful, and in many cases unjust. Patients who found genuine therapeutic benefit from compounds like BPC-157 lost access overnight when the Category 2 list dropped. People managing their weight with affordable compounded semaglutide are being priced back into the $1,200-per-month brand-name market. The regulatory framework prioritizes pharmaceutical industry economics over patient access.
But it’s also true that gray market peptides carried real risks that the community consistently downplayed. The Finnrick testing data paints a sobering picture: across thousands of independent tests, quality varies dramatically between vendors, and even the biggest names failed consistency standards. When you inject a compound without knowing exactly what’s in it, at what purity, with what contaminants, you’re making a bet with your biology.
The future of peptide access lies in the regulated market. That means 503A and 503B pharmacies, legitimate telehealth prescribers, and potentially new regulatory frameworks that balance safety with access. It means working with physicians who understand peptide therapeutics. It means paying more, waiting longer, and accepting oversight in exchange for certainty about what you’re putting in your body.
The RFK Jr. Wildcard
There’s one development that could reshape the landscape entirely. On February 27, 2026, RFK Jr. announced on Joe Rogan’s podcast (Episode #2461) that approximately 14 of 19 previously banned peptides would be moved back to Category 1, making them available again through licensed compounding pharmacies. If implemented, this would re-legalize BPC-157, Thymosin Alpha-1, AOD-9604, Semax, Selank, KPV, and MOTS-c for compounding with a prescription.
As of March 6, 2026, no formal FDA reclassification has been published. But if it happens, the irony would be remarkable: the gray market’s biggest vendor shuts down weeks before the compounds he spent years selling become legally available through pharmacies.
The peptide story is far from over. It’s just moving from the shadows into the regulated market. And how that transition plays out depends on whether regulators, legislators, and industry can build an access framework that doesn’t force patients to choose between legality and affordability.
It also means that companies like ours, ThePeptideList, serve a more important function than ever. When the market was dominated by a handful of well-known gray market vendors, finding a source was easy. Now, navigating the legitimate peptide landscape requires understanding which providers are licensed, which peptides are legal, how to evaluate quality, and what red flags to watch for.
We built this platform specifically for this moment. Not because we predicted Peptide Sciences would shut down today. But because we understood that the gray market model was always temporary, and that what comes after it requires better information, not less.
The Timeline: Peptide Sciences’ Rise and Fall
December 2009: Domain peptidesciences.com registered. Daniel Brzezinski launches the site from Henderson, Nevada, operating from a virtual mailbox at St. Rose Executive Suites. The company claims a 1990 founding date that has never been substantiated.
2010-2019: Steady growth as peptide interest rises in biohacking, bodybuilding, and longevity communities. Peptide Sciences builds reputation for professional branding, scientific content, and consistent product quality. The “research use only” model keeps them in the FDA’s peripheral vision.
2020: Proven Peptides, a competitor, shuts down abruptly. Peptide Sciences absorbs market share. The COVID-19 pandemic accelerates interest in immune-modulating peptides (Thymosin Alpha-1, BPC-157).
2021-2022: Andrew Huberman’s podcast episodes on peptides introduce millions to compounds like BPC-157 and Sermorelin. Gray market vendors see explosive demand growth.
2023: FDA issues warning letter to Peptide Sciences for making health claims about BPC-157 and TB-500. Company restructures website to comply.
October 2023: FDA designates 17 peptides as Category 2, banning them from all pharmacy compounding. BPC-157, TB-500, CJC-1295, and Ipamorelin are among them. Research peptide vendors become the only remaining source for these compounds.
Late 2023-2024: GLP-1 demand explodes. Semaglutide and tirzepatide shortages push patients toward compounding pharmacies and research peptide vendors. Revenue surges industry-wide.
October 2024: Tirzepatide shortage resolved. Compounding grace periods begin.
December 2024: FDA issues warning letters to multiple research peptide vendors (Prime Peptides, Xcel Peptides, SwissChems, Summit Research) for selling GLP-1s as unapproved drugs.
February 2025: Semaglutide shortage resolved. The GLP-1 compounding window closes.
June 2025: FDA raids Amino Asylum warehouse. Site goes permanently offline.
August 2025: Finnrick Analytics publishes E-rated test results for Peptide Sciences’ retatrutide based on 34 independent samples.
September 2025: FDA issues 50+ warning letters targeting GLP-1 compounders and manufacturers. CDER warning letters up 50% year-over-year.
Early 2026: New legislation prohibits research chemical sales of FDA-approved drug analogues. Vendors purge GLP-1s from catalogs.
February 27, 2026: RFK Jr. tells Joe Rogan that ~14 of 19 Category 2 peptides will be reclassified back to Category 1 (compounding allowed). No formal FDA action follows.
March 6, 2026: Peptide Sciences posts a three-sentence shutdown notice. The biggest name in research peptides is gone.
What Comes Next
The research peptide model, selling pharmaceutical compounds under a “not for human consumption” disclaimer, was always operating on borrowed time. Peptide Sciences proved it could work at massive scale. They also proved it couldn’t last forever.
The companies that survive the current regulatory wave will be the ones that moved into the regulated market before the gray market collapsed. Licensed compounding pharmacies. Telehealth platforms with real physician oversight. Manufacturers pursuing proper FDA pathways.
For consumers, the message is clear: the era of anonymous online peptide shopping is ending. What replaces it will be more expensive, more restrictive, and more legitimate. Whether that’s better or worse depends on whether you value access or safety more highly.
We’d argue you shouldn’t have to choose. But the current regulatory framework disagrees.
Disclaimer: ThePeptideList is an independent research and provider directory platform. We do not sell peptides, provide medical advice, or endorse the use of unregulated research chemicals. The information in this article is based on publicly available data, third-party analytics, and verified reporting. Always consult a qualified healthcare provider before beginning any peptide therapy.
Frequently Asked Questions
Why did Peptide Sciences shut down?
Peptide Sciences announced a voluntary shutdown on March 6, 2026. While the company didn’t provide specific reasons, the closure follows an unprecedented FDA enforcement campaign that included 50+ warning letters to GLP-1 vendors, a warehouse raid on competitor Amino Asylum, new legislation prohibiting research chemical sales of FDA-approved drug analogues, and independent quality testing that rated their retatrutide as “E (Bad).” The combination of regulatory pressure, loss of high-margin product lines, and erosion of quality reputation made continued operations increasingly risky.
Is Peptide Sciences coming back?
There is no indication that Peptide Sciences plans to reopen. The announcement states they have “made the decision to voluntarily shut down operations and discontinue the sale of our research products.” Unlike Proven Peptides, which returned after a multi-year hiatus, the current regulatory environment makes resuming gray market peptide sales significantly more dangerous than it was in previous years.
Where can I buy peptides now that Peptide Sciences is closed?
Legal peptide access requires a prescription from a licensed healthcare provider and a compounding pharmacy (503A or 503B). Peptides not on the FDA Category 2 list, including sermorelin, thymosin alpha-1, PT-141, and LL-37, can still be legally compounded. Our provider directory lists 823+ verified peptide providers including licensed pharmacies and telehealth clinics.
Are other research peptide vendors going to shut down too?
The regulatory trajectory points in that direction. With CDER warning letters up 50%, active warehouse raids, and new legislation targeting research chemical sales, the operating environment for gray market vendors is deteriorating rapidly. Andrew Huberman predicted that the “gray market is about to get CRUSHED,” and the evidence supports that assessment.
Did Peptide Sciences receive an FDA warning letter?
Yes. In 2023, the FDA issued a warning letter to Peptide Sciences for making health claims about BPC-157 and TB-500 on their website. The company modified their marketing to comply. This established direct regulatory contact between the FDA and Peptide Sciences years before the broader enforcement escalation of 2024-2026.
How big was Peptide Sciences?
Based on publicly available analytics, Peptide Sciences attracted approximately 1 million monthly website sessions and generated $7.45 million in online sales in December 2025 alone (per Grips Intelligence). These figures suggest the company was one of the highest-revenue operators in the entire research peptide space.
You beat me to it . Apparently they're rebranding as they've purchased new peps and it's been in the pipeline since the end of last year
Great breakdown of the state of the market! Thanks for the in depth research - subscribed!!